Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.
Gunnarsson N, Höglund M, Stenke L, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A. Gunnarsson N, et al. Among authors: stenke l. Leukemia. 2017 Aug;31(8):1825-1827. doi: 10.1038/leu.2017.131. Epub 2017 May 2. Leukemia. 2017. PMID: 28461694 Free article. No abstract available.
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Axdorph U, Stenke L, Grimfors G, Carneskog J, Hansen J, Linder O, Ljungman P, Löfvenberg E, Malm C, Simonsson B, Turesson I, Vilén L, Udén AM, Björkholm M; Swedish CML Group. Axdorph U, et al. Among authors: stenke l. Br J Haematol. 2002 Sep;118(4):1048-54. doi: 10.1046/j.1365-2141.2002.03765.x. Br J Haematol. 2002. PMID: 12199784 Free article. Clinical Trial.
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
Gruber A, Björkholm M, Brinch L, Evensen S, Gustavsson B, Hedenus M, Juliusson G, Löfvenberg E, Nesthus I, Simonsson B, Sjo M, Stenke L, Tangen JM, Tidefelt U, Udén AM, Paul C, Liliemark J. Gruber A, et al. Among authors: stenke l. Leuk Res. 2003 Apr;27(4):323-8. doi: 10.1016/s0145-2126(02)00181-9. Leuk Res. 2003. PMID: 12531223 Clinical Trial.
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.
Simonsson B, Oberg G, Bjoreman M, Bjorkholm M, Carneskog J, Karlsson K, Gahrton G, Grimfors G, Hast R, Karle H, Linder O, Ljungman P, Nielsen JL, Nilsson J, Lofvenberg E, Malm C, Olsson K, Olsson-Stromberg U, Paul C, Stenke L, Stentoft J, Turesson I, Udén AM, Wahlin A, Vilén L, Weis-Bjerrum O. Simonsson B, et al. Among authors: stenke l. Acta Haematol. 2005;113(3):155-62. doi: 10.1159/000084445. Acta Haematol. 2005. PMID: 15870485 Clinical Trial.
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
Olsson-Strömberg U, Höglund M, Björkholm M, Braide I, Carlson K, Gahrton G, Grimfors G, Hast R, Lerner R, Linder O, Ljungman P, Löfvenberg E, Malm C, Nilsson PG, Paul C, Rödjer S, Stenke L, Tidefeldt U, Turesson I, Uden AM, Wahlin A, Vilen L, Winqvist I, Zettervall O, Oberg G, Simonsson B. Olsson-Strömberg U, et al. Among authors: stenke l. Leuk Lymphoma. 2006 Sep;47(9):1768-73. doi: 10.1080/10428190600611117. Leuk Lymphoma. 2006. PMID: 17064986
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K. Mustjoki S, et al. Among authors: stenke l. Leukemia. 2009 Aug;23(8):1398-405. doi: 10.1038/leu.2009.46. Epub 2009 Mar 19. Leukemia. 2009. PMID: 19295545
131 results